Skip to main content

Vascular Diseases

3
Pipeline Programs
8
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
Percutaneous Transluminal AngioplastyPhase 41 trial
femoral-popliteal bypassPhase 41 trial
Active Trials
NCT01173094Unknown130Est. Jul 2016
NCT01171703Unknown70Est. Jul 2016
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Nicotinamide ribosidePhase 21 trial
Active Trials
NCT04040959Unknown118Est. Sep 2024
Philips
PhilipsNetherlands - Amsterdam
1 program
Angiographic run with new algorithm and low doseN/A1 trial
Active Trials
NCT01684826Completed50Est. Nov 2012
Francis Medical
Francis MedicalMN - Maple Grove
1 program
ElucidVivoN/A1 trial
Active Trials
NCT05524896Completed302Est. Jul 2022
LeMaitre Vascular
LeMaitre VascularAustralia - Docklands
1 program
Implant the XenoSure patchN/A1 trial
Active Trials
NCT03173703Active Not Recruiting144Est. Nov 2025
Artivion
ArtivionKENNESAW, GA
1 program
PhotoFixN/A2 trials
Active Trials
NCT05314868Terminated10Est. Nov 2022
NCT03669042Completed94Est. Jul 2020
Shockwave Medical
Shockwave MedicalCA - Santa Clara
1 program
ShockwaveN/A1 trial
Active Trials
NCT04600934Withdrawn0Est. Sep 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsfemoral-popliteal bypass
UNION therapeuticsPercutaneous Transluminal Angioplasty
Colorado TherapeuticsNicotinamide riboside
Shockwave MedicalShockwave
ArtivionPhotoFix
ArtivionPhotoFix
LeMaitre VascularImplant the XenoSure patch
Francis MedicalElucidVivo
PhilipsAngiographic run with new algorithm and low dose

Clinical Trials (9)

Total enrollment: 918 patients across 9 trials

NCT01171703UNION therapeuticsfemoral-popliteal bypass

Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I)

Start: Nov 2010Est. completion: Jul 201670 patients
Phase 4Unknown
NCT01173094UNION therapeuticsPercutaneous Transluminal Angioplasty

Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II)

Start: Aug 2010Est. completion: Jul 2016130 patients
Phase 4Unknown
NCT04040959Colorado TherapeuticsNicotinamide riboside

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Start: Nov 2019Est. completion: Sep 2024118 patients
Phase 2Unknown
NCT04600934Shockwave MedicalShockwave

Shockwave Assisted Large Bore Access

Start: Oct 2022Est. completion: Sep 20230
N/AWithdrawn
NCT05314868ArtivionPhotoFix

Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery

Start: Mar 2022Est. completion: Nov 202210 patients
N/ATerminated
NCT03669042ArtivionPhotoFix

Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

Start: Nov 2018Est. completion: Jul 202094 patients
N/ACompleted
NCT03173703LeMaitre VascularImplant the XenoSure patch

Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair

Start: Jul 2017Est. completion: Nov 2025144 patients
N/AActive Not Recruiting
NCT05524896Francis MedicalElucidVivo

Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography

Start: Jan 2017Est. completion: Jul 2022302 patients
N/ACompleted
NCT01684826PhilipsAngiographic run with new algorithm and low dose

X-ray Dose Reduction Study for Cardiac Angiography and Intervention

Start: Sep 2012Est. completion: Nov 201250 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.